Buradasınız

Anasayfa » Content

Tip 4 Kardiyorenal Sendromda Ultrafi ltrasyon Diüretiklerden Daha Üstün Değildir

Ultrafi ltration is not Superior than Diuretics in Type 4 Cardiorenal Sydrome

Journal Name:

  • Türk Nefroloji, Diyaliz ve Transplantasyon Dergisi

Publication Year:

  • 2014
DOI: 
10.5262/tndt.2014.1001.05

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
OBJECTIVE: Cardiorenal syndrome (CRS) describes a dysregulation of the heart and kidneys affecting each other. Recently hemodialysis treatments were used more frequently. Aim was to analyze the effects of conventional diuretic and UF treatments. MATERIAL and METHODS: Thirty-four Type 4 CRS diagnosed patients were included. Baseline characteristics were recorded. Echocardiography measured at the admission and at the end of the treatment. RESULTS: The mean age 67.4±9.3 (51-93) years and follow-up period were 15.9±11.5 months. The patients were grouped as diuretic group, n=12 and UF group, n=22. At the beginning mitral valve A wave, blood urea nitrogen and creatinine values were higher in the UF group while creatinine values were higher in the UF group compared to diuretic group at the end of the study. Although basal ejection fraction (EF) values were not different, it was higher in the UF group at the end of the study (42.38±12.70 % and 29±3.67 %, p <0.05). During follow-up mortality rates were not different in both groups (diuretic group, 6 patients (17.6 %), the UF group 1 patient (2.9 %), (p> 0.05). CONCLUSION: In Type 4 CRS, mortality and hospital admissions were not reduced by UF treatment but cardiac function assessed by EF was signifi cantly improved suggesting this therapy to be benefi cial in appropriate patients.
Bookmark/Search this post with
Abstract (Original Language): 
AMAÇ: Kardiyorenal sendrom (KRS) birbirlerini etkileyen kalp ve böbrek bozukluklukları olarak tanımlanır. Son zamanlarda bu alanda hemodiyaliz tedavisi tercihi artmıştır. Bu çalışmada amaç geleneksel diüretik ve UF tedavilerinin etkilerini karşılaştırmaktır. GEREÇ ve YÖNTEMLER: Çalışmaya Tip 4 KRS tanısı konulan 34 hasta alındı. Hastaların bazal özellikleri kaydedildi. Başlangıçta ve tedavinin sonunda ekokardiyografi k değerlendirme yapıldı. BULGULAR: Hastaların yaş ortalaması 67.4 ± 9.3 (51-93) yıl ve takip süresi 15.9 ± 11.5 ay idi. Hastalar diüretik, n = 12 ve UF grubu, n = 22 olarak sınıfl andırıldı. Çalışmanın başında mitral kapak A dalgası, kan üre nitrojeni ve kreatinin değerleri UF grubunda yüksek, çalışmanın sonunda UF grubunda kreatinin değerleri diüretik grubuna göre daha yüksek olarak bulundu. Bazal ejeksiyon fraksiyonu (EF) değerleri her iki grupta farklı olmamasına rağmen UF grubunda çalışmanın sonunda bazale göre artış mevcuttu (42.38 ± 12.70 ve% 29 ± 3.67%, p <0.05). Takip sırasında ölüm oranları her iki grupta farklı değildi (diüretik grubu, 6 hastada (% 17.6), UF grubu 1 hasta (% 2.9), (p> 0.05). SONUÇ: Tip 4 Kardiyorenal sendromda, UF tedavisi uygulananlarda mortalite ve hastaneye başvurular azalmasa da EF ile değerlendirilen kardiyak fonksiyonlarda anlamlı olarak düzelme olması ile seçilmiş hastalarda bu tedavi etkili olabilir..
FULL TEXT (PDF): 
PDF icon arastirmax-tip-4-kardiyorenal-sendromda-ultrafi-ltrasyon-diuretiklerden-daha-ustun-degildir.pdf
  • 1
20
25
  • Turkish

REFERENCES

References: 

1. Heywood JT: The cardiorenal syndrome: Lessons from the
ADHERE database and treatment options. Heart Fail Rev 2004; 9:
195-201
2. Forman DE, Butler J, Wang Y, Abraham WT, O’Connor CM,
Gottlieb SS, Loh E, Massie BM, Rich MW, Stevenson LW, Young
JB, Krumholz HM: Incidence, predictors at admission, and impact
of worsening renal function among patients hospitalized with heart
failure. J Am Coll Cardiol 2004; 43: 61-67
3. Smith GL, Lichtman JH, Bracken MB, Shlipak MG, Phillips
CO, DiCapua P, Krumholz HM: Renal impairment and outcomes
in heart failure: Systematic review and meta-analysis. J Am Coll
Cardiol 2006; 47: 1987-1996
4. Lassus J, Harjola VP, Sund R, Siirilä-Waris K, Melin J, Peuhkurinen
K, Pulkki K, Nieminen MS; FINN-AKVA Study group: Prognostic
value of cystatin C in acute heart failure in relation to other markers
of renal function and NT-proBNP. Eur Heart J 2007; 28: 1841-18475. van Kimmenade RR, Januzzi JL Jr, Baggish AL, Lainchbury JG,
Bayes-Genis A, Richards AM, Pinto YM: Amino-terminal pro-brain
natriuretic Peptide, renal function, and outcomes in acute heart
failure: Redefi ning the cardiorenal interaction? J Am Coll Cardiol
2006; 48: 1621-1627
6. Naruse H, Ishii J, Kawai T, Hattori K, Ishikawa M, Okumura M, Kan
S, Nakano T, Matsui S, Nomura M, Hishida H, Ozaki Y: Cystatin C
in acute heart failure without advanced renal impairment. Am J Med
2009; 122: 566-573
7. Ronco C, Haapio M, House AA, Anavekar N, Bellomo R:
Cardiorenal syndrome. J Am Coll Cardiol 2008; 52: 1527-1539
8. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De
Simone G, Ferguson TB, Ford E, Furie K, Gillespie C, Go A,
Greenlund K, Haase N, Hailpern S, Ho PM, Howard V, Kissela B,
Kittner S, Lackland D, Lisabeth L, Marelli A, McDermott MM,
Meigs J, Mozaffarian D, Mussolino M, Nichol G, Roger VL,
Rosamond W, Sacco R, Sorlie P, Roger VL, Thom T, Wasserthiel-
Smoller S, Wong ND, Wylie-Rosett J; American Heart Association
Statistics Committee and Stroke Statistics Subcommittee: Heart
disease and stroke statistics-2010 update: A report from the
American Heart Association. Circulation 2010; 121(7): e46-e215
9. Ahmed A, Allman RM, Fonarow GC, Love TE, Zannad F, Dell’italia
LJ, White M, Gheorghiade M: Incident heart failure hospitalization
and subsequent mortality in chronic heart failure: A propensitymatched
study. J Card Fail 2008; 14(3): 211-218
10. Forster HP, Emanuel E, Grady C: The 2000 revision of the
Declaration of Helsinki: A step forward or more confusion? Lancet
2001; 358(9291): 1449-1453
11. Kidney Disease: Improving Global Outcomes (KDIGO) Acute
Kidney Injury Work Group. KDIGO Clinical Practice Guideline for
Acute Kidney Injury. Kidney Int Suppl 2012; 2: 1-138
12. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R,
Feigenbaum H, Gutgesell H, Reichek N, Sahn D, Schnittger
I: Recommendations for quantifi cation of left ventricle by
two-dimensional echocardiography. American Society of
Echocardiography Committee on Standards, Subcommitee on
Quatifi cation of Two-Dimensional Echocardiograms. J Am Soc
Echocardiogr 1989; 2: 358-367
13. Feigenbaum H, Armstrong WF, Ryan T: Evaluation of systolic
and diastolic function of the left venticle. In: Feigenbaum H, eds.
Feigenbaum’s Echocardiography Sixth Edition. Lippincott Williams
and Wilkins, Hagerstown, USA; 2005. p142-p145
14. Nissenson AR, Berns JS, Lerma EV: Current Diagnosis &
Treatment. Nephrology & Hypertension, New York, NY: McGraw-
Hill, 200915. Drazner MH, Rame JE, Stevenson LW, Dries DL: Prognostic
importance of elevated jugular venous pressure and a third heart
sound in patients with Heart Failure. N Engl J Med 2001; 345(8):
574-581
16. Brater DC: Diuretic therapy. N Engl J Med 1998; 339(6): 387-395
17. Ahmed A: Use of angiotensin-converting enzyme inhibitors in
patients with heart failure and renal insuffi ciency: How concerned
should we be by the rise in serum creatinine? J Am Geriatr Soc
2002; 50(7): 1297-1300
18. Núñez J, Núñez E, Miñana G, Bodí V, Fonarow GC, Bertomeu-
González V, Palau P, Merlos P, Ventura S, Chorro FJ, Llàcer P,
Sanchis J: Differential mortality association of loop diuretic dosage
according to blood urea nitrogen and carbohydrate antigen 125
following a hospitalization for acute heart failure. Eur J Heart Fail
2012; 14(9): 974-984
19. De Vecchis R, Ciccarelli A, Ariano C, Cioppa C, Giasi A,
Pucciarelli A, Cantatrione S: In chronic heart failure with marked
fl uid retention, the i.v. high doses of loop diuretic are a predictor
of aggravated renal dysfunction, especially in the set of heart
failure with normal or only mildly impaired left ventricular systolic
function. Minerva Cardioangiol 2011; 59(6): 543-554
20. Blair JE, Pang PS, Schrier RW, Metra M, Traver B, Cook T,
Campia U, Ambrosy A, Burnett JC Jr, Grinfeld L, Maggioni AP,
Swedberg K, Udelson JE, Zannad F, Konstam MA, Gheorghiade
M; EVEREST Investigators: Changes in renal function during
hospitalization and soon after discharge in patients admitted for
worsening heart failure in the placebo group of the EVEREST trial.
Eur Heart J 2011; 32(20): 2563-2572
21. Massie BM, O’Connor CM, Metra M, Ponikowski P, Teerlink
JR, Cotter G, Weatherley BD, Cleland JG, Givertz MM, Voors A,
DeLucca P, Mansoor GA, Salerno CM, Bloomfi eld DM, Dittrich
HC; PROTECT Investigators and Committees: Rolofylline, an
adenosine A1-receptor antagonist, in acute heart failure. N Eng J
Med 2010; 363: 1419-1428
22. Ali SS, Olinger CC, Sobotka PA, Dahle TG, Bunte MC, Blake D,
Boyle AJ: Loop diuretics can cause clinical natriuretic failure: A
prescription for volume expansion. Congest Heart Fail 2009; 15:
1-4
23. Ross EA, Bellamy FB, Hawig S, Kazory A: Ultrafi ltration for acute
decompensated heart failure: Cost, reimbursement, and fi nancial
impact. Clin Cardiol 2011; 34: 273-277

Thank you for copying data from http://www.arastirmax.com